How Pragmatic Can Post-Approval Safety Trials Be?
This article was originally published in RPM Report
Executive Summary
The February 23 meeting of the Pulmonary Allergy Drugs Advisory Committee included an interesting colloquy on the potential use of pragmatic trials to answer real-world use and safety questions. FDA Division of Pulmonary, Allergy and Rheumatology Director Badrul Chowdhury began the discussion by questioning a reference to “pragmatic trials” by the Chari of the committee, Jerry Krishnan (University of Illinois Hospital & Health Sciences System).
You may also be interested in...
Believing In Biosimilars: Industry Takes Long View on FDA Pathway
FDA is open for business on biosimilars as it works out the specifics of the new review pathway. But for companies considering an entry into the space, two big questions still remain: Does a profitable market exist, and how conservative will FDA be on those initial approvals? Executives from across the biopharmaceutical industry weigh in during The RPM Report’s FDA/CMS Summit.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.